Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

67 results about "Neuronal Nitric Oxide Synthase" patented technology

Neuronal nitric oxide synthase is important to scientists because of the importance of nitric oxide in the human body. Neuronal nitric oxide synthase is mainly responsible for synthesizing nitric oxide in the neural tissue and the skeletal muscle1,3.

Methods for suppressing the induction of nitric oxide synthase in a cell

Disclosed are methods for suppressing the induction of inducible nitric oxide synthase in a cell comprising contacting said cell with an effective amount of at least one induction suppressor of inducible nitric oxide synthase or a cytokine are disclosed. The induction suppressor can be an inhibitor of mevalonate synthesis, an inhibitor of the farnesylation of Ras, an antioxidant, an enhancer of intracellular cAMP, an enhancer of protein kinase A (PKA), an inhibitor of NF-kβ activation, an inhibitor of Ras / Raf / MAP kinase pathway, an inhibitor of mevalonate pyrophosphate decarboxylase or an inhibitor of farnesyl pyrophosphate.
Owner:MUSC FOUND FOR RES DEV

Quinoline derivative, preparation method and medical use thereof

The invention discloses a making method of compound I and drug composition and application to treat tumour, which is 3-nitrile quinoline derivant (I) as dual-inhibitor protein kinase of tyrosine and nitric oxide synthase, wherein G1, G2, G3, G4, X, Z and n are defined as instruction.
Owner:CHINA PHARM UNIV

Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds

The present invention describes novel nitrosated and / or nitrosylated α-adrenergic receptor antagonists, and novel compositions containing at least one nitrosated and / or nitrosylated α-adrenergic receptor antagonist, and, optionally, one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or are a substrate for nitric oxide synthase, and / or one or more vasoactive agents. The present invention also provides novel compositions containing at least one α-adrenergic receptor antagonist, and one or more compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, stimulate endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and / or one or more vasoactive agents. The present invention also provides methods for treating or preventing sexual dysfunctions in males and females, for enhancing sexual responses in males and females, and for treating or preventing benign prostatic hyperplasia, hypertension, congestive heart failure, variant (Printzmetal) angina, glaucoma, neurodegenerative disorders, vasospastic diseases, cognitive disorders, urge incontinence, or overactive bladder, and for reversing the state of anesthesia.
Owner:NITROMED

Method of stimulating nitric oxide synthase

InactiveUS6465516B1Preventing, treating, arresting, or ameliorating disease conditionsAmeliorate and avoid tachycardiaBiocidePeptide/protein ingredientsDiseaseHMG-CoA reductase
A method for treating a subject who would benefit from increased nitric oxide production comprising administering inhibitors of Hmg-CoA-Reductase is disclosed for the treatment of diseases related to endothelial dysfunction.
Owner:PALMETTO PHARMA

Aniline derivatives possessing an inhibitory effect of nitric oxide synthase

Compounds represented by the general formula (1): (where R1 is SR6 or NR7R8, where R6 is typically an alkyl group having 1-6 carbon atoms, R7 is a hydrogen atom, an alkyl group having 1-6 carbon atoms or a nitro group, and R8 is a hydrogen atom or an alkyl group having 1-6 carbon atoms; R2 and R3 are each typically a hydrogen atom or an alkyl group having 1-6 carbon atoms; R4 is a hydrogen atom, an alkyl group having 1-6 carbon atoms or an amidino group of which the amine portion may be substituted by an alkyl or nitro group; R5 is a hydrogen atom or an alkyl group having 1-6 carbon atoms; Y1, Y2, Y3 and Y4 which may be the same or different are each typically a hydrogen atom, a halogen atom or an alkoxy group having 1-6 carbon atoms; n and m are each an integer of 0 or 1), or possible stereoisomers or optically active forms of the compounds or pharmaceutically acceptable salts thereof. The compounds possess a potent nitric oxide synthase inhibiting activity and are useful as therapeutics of cerebrovascular diseases.
Owner:CHUGAI PHARMA CO LTD

Method for treating tension-type headache with inhibitors of nitric oxide and nitric oxide synthase

Tension-type headache is treated by interacting with neuronal transmission in relation to pain in connection with headache in a way which prevents or decreases sensitization of second order nociceptive neurons. In particular, treatment is performed by administration of an effective amount of a substance which prevents or decreases central sensitization. Important examples of such substances are substances which interact with nitric oxide, such as nitric oxide synthase (NOS) inhibitors, such as L-NMMA or L-NAME or L-NIO or L-NNA. According to a broader aspect of the invention tension-type headache is treated by administration of substances which are effective in preventing or decreasing pain in connection with tension-type headache, such as the substances mentioned above. Accordingly, the invention relates to treatment of tension-type headache by administration of substances which substantially inhibit the activity of nitric oxide synthase (NOS), such as NOS inhibitors, such as L-NMMA or L-NAME or L-NIO or L-NNA.
Owner:NEURAXON INC

Substituted benzimidazole compounds with dual NOS inhibitory activity and mu opioid agonist activity

The present invention relates to benzimidazole compounds having dual nitric oxide synthase (NOS) inhibitory activity and agonist activity at the mu-opioid receptor, to pharmaceutical and diagnostic compositions containing them, and to their medical use, particularly as compounds for the treatment or prevention of chronic pain, acute pain, migraine, and neuropathic pain.
Owner:NEURAXON INC

Inducible nitric oxide synthase for treatment of disease

InactiveUS20020061862A1Increase local nitric oxide concentrationAvoid tissue damageVectorsPeptide/protein ingredientsDiseaseA-DNA
The invention provides a pharmaceutical composition comprising as an active ingredient a pharmaceutical agent comprising a DNA sequence that codes for a protein which possesses the biological activity of inducible nitrogen monoxide synthase (iNOS) and eukaryotic regulation elements, wherein the eukaryotic regulation elements result in the expression of said DNA sequence in eukaryotic cells, and a pharmaceutically acceptable carrier. The pharmaceutical agent can be complexed to liposomes.
Owner:UNIVERSITY OF PITTSBURGH

Selective inhibition of neuronal nitric oxide synthase

Compositions, prodrugs and methods for inhibiting neural Nitric Oxide Synthase (nNOS). By inhibiting nNOS, the compounds, prodrugs and methods of the presnet invention are useable to treat or prevent disorders in human or veterinary patients that are caused, mediated or agrevated by Nitric Oxide within the body.
Owner:RGT UNIV OF CALIFORNIA +1

Selective neuronal nitric oxide synthase inhibitors with azole substituents

ActiveUS8618143B1Sufficient lipophilicityMaintaining potency and selectivityBiocideOrganic chemistryBioavailabilityNeuronal Nitric Oxide Synthase
Non-peptide, azole-substituted nitric oxide snythase inhibitor compounds, compositions and related methods, as can be used to enhance bioavailability and inhibit production of nitric oxide.
Owner:NORTHWESTERN UNIV

Medicine composition containing budesonide and nitric oxide synthase (NOS) inhibitor and for treating nose inflammation

A medicine composition containing budesonide and a nitric oxide synthase (NOS) inhibitor and for treating nose inflammation comprises the budesonide serving as an active constituent, an amino acid derivative serving as the NOS inhibitor, one or more types of medicine auxiliary materials suitable for nose medicine dosing and the balance water.
Owner:TIANJIN JINYAO GRP

Inhalation drug composition with fluticasone propionate and nitric oxide synthase (NOS) inhibitor

InactiveCN103127133ALower serum IgE, IL-4Reduce IL-5 contentOrganic active ingredientsPharmaceutical delivery mechanismFluticasone propionateMedicine
An inhalation drug composition with fluticasone propionate and a nitric oxide synthase (NOS) inhibitor comprises the fluticasone propionate which serves as an active ingredient, an amino acid derivative which serves as the NOS inhibitor and one or more drug auxiliary materials which suit to be inhaled.
Owner:TIANJIN JINYAO GRP

Thiophene-2-carboximidamide Based Selective Neuronal Nitric Oxide Inhibitors

ActiveUS20140066635A1Improved bioavailability-includingOrganic chemistryTerthiopheneNeuronal nitric oxide
Selective neuronal nitric oxide synthase (nNOS) inhibitor compounds designed with one or more thiophene-2-carboximidamide substituents for improved bioavailability.
Owner:NORTHWESTERN UNIV

Injection medicine composition containing glucocorticoid and NOS (nitric oxide synthase) inhibitor

The invention discloses an injection medicine composition containing glucocorticoid and NOS (nitric oxide synthase) inhibitor, containing glucocorticoid which is used as an active ingredient, NOS inhibitor, and one or more pharmaceutical excipients suitable for injection.
Owner:TIANJIN JINYAO GRP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products